January 17, 2025 07:00 AM ESTUpdated 10:15 AM

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down

Alex Hoffman

Copy Chief

Kathy Wong

Editor

→ Spark co-founder Kathy High made a quiet return to eye disease drug development, becoming CEO of US-Swiss biotech RhyGaze “late last year,” the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Sage sues Biogen days after $469M buyout offer

Ozempic makes list for next round of Medicare drug price negotiations

Novo claims high-dose Phase 3 Wegovy win but sales impact might be muted

What Trump's CMS can and can't change with the second round of drug price negotiations

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

Roche's cardiometabolic chief warns against weight loss 'obsession' with GLP-1s

Kathy High leads GV, ARCH-backed eye dis­ease biotech; Arv­inas com­mer­cial ex­ec steps down

Copy Chief

Editor

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down